Integrating Oncology Lessons Across Tumor Types From Kidney to Prostate—A Good-Risk Shift

This Viewpoint discusses whether intensive treatment is always necessary from the outset in patients with metachronous, low-volume disease.

Corresponding Author: Giandomenico Roviello, MD, PhD, Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Viale Pieraccini 6, 50139, Florence, Italy (giandomenico.roviello@unifi.it).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.